Near-Infrared Spectroscopy and Ultrasound Investigation of Coronary Artery Plaque (LUNAR)

Lipiscan and Ultrasound Interrogation of Atherosclerotic Coronary Arteries (LUNAR)

The primary objective of this study is to characterize coronary artery blockages as determined by the LipiScan combined NIRS-IVUS catheter using multi-vessel imaging.

Study Overview

• Status: Withdrawn
• Conditions: Coronary Artery Disease; Atherosclerosis
• Intervention / Treatment: Device: NIRS/IVUS of coronary artery

Detailed Description

This is a prospective, observational, single-center registry that will enroll 100 patients. All patients presenting to Beaumont Hospital for elective invasive coronary angiography and possible ad hoc percutaneous coronary intervention balloon angioplasty will be considered for inclusion. Patients must meet all inclusion and exclusion criteria prior to consent. All information requested as part of this study will be obtained from clinical data as part of each subject's standard medical care. Cardiac catheterization and percutaneous coronary intervention will be performed according to standard guidelines and clinical practice. All aspects of clinical care of the patient will follow routine standards as determined by institutional policies, published clinical practice guidelines, and the treating physician.

After completion of routine invasive coronary angiography and upon determining that the patient has either (1) an epicardial de novo coronary artery lesion of indeterminate severity (>50% to <70% stenosis) that requires IVUS analysis for further delineation of stenosis (blockage) severity; or (2) a severe epicardial de novo coronary artery lesion that requires PCI for definitive treatment, combined NIR-IVUS imaging will be carried out in the target-vessel. Upon completion of NIRS-IVUS imaging of the target-vessel, percutaneous intervention will be performed in the standard fashion if deemed clinically appropriate. Upon completion of target-vessel intervention, NIRS-IVUS imaging will then be repeated in the target-vessel.

Upon completion of the treatment of the target-vessel, NIRS-IVUS will be performed in any other major epicardial vessel containing a stenosis ≥30% if deemed appropriate by the treating cardiologist.

Patients will be carefully monitored throughout their hospital stay and will be followed either by office visit or by telephone at 6 months (± 7 days); 12 months (± 14 days); 24 months (± 30 days); 36 months (± 30 days); 48 months (± 30 days); and 60 months (± 30 days).

The patient's medical records will be accessed to collect data about medical history and activities during the course of the study. All data will be collected by using standard case report forms. Follow up data after discharge will be collected using a phone script questionnaire . All data forms will include unique study identifiers to protect the participants personal identity. All data will be recorded in an Excel spreadsheet and kept on a secure computer requiring password entry.

There are no additional required medical procedures as part of this protocol beyond the use of the NIRS-IVUS catheter during the index procedure.

• Study Type: Observational

Contacts and Locations

Study Locations

• United States
  • Michigan
    • Royal Oak, Michigan, United States, 48073
      • Beaumont Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

All patients presenting to Beaumont Hospital for elective invasive coronary angioplasty and possible percutaneous intervention.

Description

Inclusion Criteria:

1. Subject is at least 18 years of age;
2. Subject is scheduled for elective, clinically-indicated, invasive coronary angiography;
3. Subject is willing and able to provide informed written consent prior to invasive angiography;
4. Combined NIRS-IVUS is not contra-indicated per the cardiologist performing invasive coronary angiography; and
5. Patient has either: (a) An epicardial coronary artery stenosis of intermediate severity (>50% to <70% stenosis)by invasive angiography in whom IVUS is planned to further evaluate lesion severity; or (b) A severe epicardial coronary artery stenosis by invasive angiography and percutaneous coronary intervention (PCI) is planned for definitive treatment.

Exclusion Criteria:

1. Subject life expectancy at time of invasive angiography is less than 2 years;
2. Subject is pregnant or suspected to be pregnant;
3. Subject is unable to provide informed consent;
4. Any factor deemed by the treating cardiologist to put the patient at increased risk of participating in the protocol (i.e. coronary artery anatomy is not suitable for traditional IVUS secondary to severe tortuousity or excessive calcification).
5. Bacteremia or sepsis,
6. Major coagulation system abnormalities,
7. Severe hemodynamic instability or shock,
8. Patients diagnosed with coronary artery spasm,
9. Patients disqualified for CABG surgery,
10. Total occlusion,
11. Patients disqualified for PTCA,
12. Patients who are not suitable for IVUS procedures.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

NIRS/IVUS of coronary artery; All patients will have an epicardial coronary artery stenosis of intermediate severity (>50% to <70% stenosis) (stenosis ≥20% - ≤70%) by invasive angiography in whom IVUS is planned to further clinical evaluation of lesion severity; or a severe epicardial coronary artery stenosis by invasive angiography and percutaneous coronary intervention (PCI) is planned for definitive treatment.

Device: NIRS/IVUS of coronary artery; Evaluation of coronary plaque by NIRS/IVUS.; Other Names: Infraredx

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Near-Infrared Spectroscopy and Ultrasound Investigation of Coronary Artery Plaque	The primary objective of this study is to characterize coronary artery blockages as determined by the Lipiscan combined NIRS-IVUS catheter in multiple coronary arteries.	1 year

Collaborators and Investigators

• Sponsor: William Beaumont Hospitals
• Investigators: Principal Investigator: Simon R Dixon, MBChB, William Beaumont Hospitals

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2011
• Primary Completion (Actual): October 1, 2013
• Study Completion (Actual): October 1, 2013

Study Registration Dates

• First Submitted: December 7, 2012
• First Submitted That Met QC Criteria: December 7, 2012
• First Posted (Estimate): December 11, 2012

Study Record Updates

• Last Update Posted (Actual): January 9, 2018
• Last Update Submitted That Met QC Criteria: January 6, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Coronary Artery Disease; Atherosclerosis
• Other Study ID Numbers: 2011-258

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED